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ABSTRACT 
Objectives: To describe the effects of various short zidovudine 
(ZDV) prophylactic regimens on vertical transmission of human 
immunodeficiency virus type 1 (HIV-I) infection, especially the 
effect of immediate neonatal ZDV prophylaxis. 
Materials and Methods: The study included children of HIV-l - 
infected mothers who were born at a teaching hospital in 
Bangkok. The ZDV prophylaxis regimens varied by time peri- 
ods that included: (1) no ZDV (1991-1996); (2) antenatal oral 
ZDV 250 mg given twice a day starting at 34 to 36 weeks ges- 
tation and continued until labor (1995-l 998); (3) antenatal oral 
ZDV plus immediate neonatal oral ZDV, 6 mg/0.6 mUdose 
started within the first 2 hours after birth and continued at 6- 
hour intervals for 4 to 6 weeks (1997-1998); and (4) intra- 
partum intravenous ZDV given in addition to regimen 3 
(1998-1999). Neonatal ZDV was administered within 2 hours 
after birth in 95% of the neonates. 
Results: In a cohort of 136 children born at least 9 months 
before the analysis date, the HIV-I vertical infection rates were: 
(1) no ZDV, 11 of 48 (22.9%, 95% confidence interval 
[Cl] = 12.0-37.3); (2) late antenatal ZDV, IO of 47 (21.3%, 95% 
Cl = 10.7-35.7); (3) late antenatal ZDV plus immediate neona- 
tal ZDV, 0 of 28 (O%, 95% Cl = O-l 2.3); (4) late antenatal, intra- 
pat-turn intravenous ZDV, plus immediate neonatal ZDV, 0 of 
13 (O%, 95% Cl = O-24.7). An estimated 0% (95% Cl = O-8.6) 
of the infants who received immediate neonatal ZDV with or 
without intrapartum ZDV were infected, as compared with 
22.1% (95% Cl = 14.2-31.8 ) of those who received no ZDV 
or only late antenatal ZDV (P < 0.001). 
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Conclusion: The results of this study suggests high protective 
effect of immediate administration of neonatal ZDV, Perinatal 
components of antiretroviral prophylaxis provided the best 
results for protecting against vertical HIV-I transmission. 
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Zidovudine (ZDV) therapy has proved effective in reduc- 
ing human immunodeficiency virus type 1 (HIV-l) trans- 
mission from infected pregnant women to their infants 
in randomized double-blind placebo-controlled trials in 
both non-breastfeeding and breastfeeding infants.1-4 The 
Pediatric AIDS Clinical Trials Group protocol 076 showed 
that an intensive regimen of ZDV prophylaxis starting at 
14 to 34 weeks’ gestation, given intravenously during 
labor and delivery, and orally to the neonates for the first 
6 weeks of life reduced the risk of vertical HIV trans- 
mission by two-thirds.’ A shorter oral ZDV regimen begin- 
ning at 36 weeks of gestation, given orally during labor, 
without a neonatal component also reduced the risk of 
transmission by approximately TO%.* 
Limited observational data suggest that the use of 
abbreviated ZDV regimens beginning intrapartum or in 
the first 48 hours of life had some protective effects.5,” 
Some evidence also suggests that giving the drug sooner 
after HIV exposure would be better.‘-” This report 
describes the effect of immediate neonatal ZDV prophy- 
laxis as well as failure of a regimen consisting of only 
late antenatal ZDV given twice daily to prevent vertical 
HIV-l infection in non-breastfed neonates. 
PATIENTS AND METHODS 
Participants 
The study was carried out at Ramathibodi Hospital, a 
teaching hospital in Bangkok, which serves a mixed pop- 
ulation of lower and middle socioeconomic class people. 
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The annual delivery rate is approximately 8000 of which 
99% registered at 6 to 14 weeks of gestation. Routine vol- 
untary antenatal anti-HIV screening tests with counseling 
have been practiced since 1990. The tests were performed 
at first registration for antenatal care during the first 
trimester and were repeated at week 32 of pregnancy 
The study included all pregnant women who had 
tested anti-HIV positive, decided to continue pregnancy, 
and had deliveries at Ramathibodi Hospital between 
November 1991 and February 1999. All deliveries by HIV- 
infected mothers were assisted by obstetricians or resi- 
dents training in obstetrics and gynecology. The first 
infant delivered by an HIV-infected mother at this hospital 
was born in November 199 1. 
Prophylaxis Regimens and Follow-up 
stayed in the hospital during the first 3 days of life, dur- 
ing which oral ZDV was given by nurses every 6 hours 
after the first dose. A bottle of 100 mL ZDV syrup was 
given to the mothers on discharge from the hospital. The 
mothers were trained by pediatricians or nurses about 
administration of ZDV syrup to the infants, and medica- 
tion practice was checked at the l-month visit. Medical 
and social care for the families were provided. 
Laboratory Methods 
Anti-HIV tests were performed at the immunology labo- 
ratory of this hospital, using commercially available tests 
(AxSYM HIV-l/HIV-2, Abbott Laboratories, Chicago, Illi- 
nois; and SERODLA-HIV; Fujirebio Inc., Tokyo, Japan), fol- 
Since January 1995, HIV-infected women have been given 
drugs has improved. Zidovudine prophylaxis practices 
included: 
information about ZDV prophylaxis. Regimens have 
changed as information about and affordability of the 
lowing the manufacturers’ instructions. Pregnant women 
were confirmed to be positive to anti-HIV antibody with 
the Western blot technique. 
Outcome Assessment 
Group 1. No ZDV (1991-1996) 
Group 2. Antenatal oral ZDV 250 mg (Retrovi?, Glaxo, 
Wellcome Operations, Greenfort, UK) given orally 
twice daily starting at 34 to 36 weeks and continued 
until labor without intrapartum ZDV (1995- 1998) 
Group 3. In addition to the regimen used in group 2, 
neonatal ZDV syrup (Retrovir, Glaxo) 6 mg/O.G 
ml/dose given orally every 6 hours starting as soon 
as possible after birth and continued for 4 to 6 weeks 
and regularly after that according to the well-child care 
schedule. Blood tests for anti-HIV were performed at 6, 
All infants were followed prospectively at the pediatric 
9,12, and 15 or 18 months of age. 
infectious disease clinic. Thev were evaluated at 1 month 
Children were classified as uninfected if they had 
negative anti-HIV tests twice between the ages of 8 and 
15 months or a negative anti-HIV test once at 15 to 18 
months. Criteria for the diagnosis of HIV infection 
included persistence of HIV antibodies at or after 15 to 
18 months of age. 
(1997-1998) 
Group 4. In addition to the regimen used in group 3, 
Statistical Analyses 
intrapartum injectable ZDV (Retrovir, Glaxo) 2 mg/kg 
of body weight, given intravenously for 1 hour, fol- 
lowed by 1 mg/kg per hour until delivery 
(1998-1999). 
There were two pairs of alternate periods of practice 
between group 2 and group 3 during April 1995 to 
December 1998. Oral ZDV syrup had been given to 
neonates during January to August 1997, and was not 
given during September 1997 to January 1998, because 
the donated ZDV syrup had been consumed and because 
some preliminary information suggested that the neona- 
tal component might be unimportant when antenatal 
prophylaxis was given. It was started again in January 
1998, when it had been noted that, by stopping the drug, 
the transmission rate seemed to increase. 
All women were counseled not to breastfeed and lac- 
tation inhibition hormone was given. Compliance to the 
oral ZDV regimen by pregnant women was observed by 
pill counts at each weekly visit. Administration of oral 
ZDV syrup to neonates as soon as possible after birth 
was recommended practice at this hospital. The infants 
For continuous data, Student’s t-test was used if the 
assumption of normal distribution was met; if not, 
Kruskal-Wallis test was applied. For qualitative data, chi- 
squared test was used, and Fisher’s exact test was applied 
if the numbers of expected values were less than 5 in 
more than 20% of all cells. Exact confidence intervals 
(CI) were calculated for relative risk (RR) and propor- 
tions. Stata Statistical Software on a microcomputer was 
used for all calculations.‘” 
RESULTS 
Characteristics of Mothers and Infants 
A total of 136 HIV-infected pregnant women delivered 
at, Ramathibodi Hospital during the study period. All 
women had acquired HIV infection by sexual contacts, 
and none had a history of drug injection. Characteristics 
of mothers and infants in the study are presented in 
Table 1. Forty-eight mother-infant pairs did not receive 
any ZDV (group l), 47 received late antenatal ZDV 
(group 2) 28 received neonatal ZDV syrup in addition 
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Table 1. Characteristics of Mothers and Infants in the Study 
Characteristics 
Group 1 
No ZDV 
n = 48 
Group 2 
Antenatal 
ZDV 
n=47 
Group 3 
Antenatal & 
Neonatal ZDV 
n=28 
Group 4 
Antenatal, lntrapartum 
& Neonatal ZDV 
n = 13 P-Value 
Mothers 
Median age (y) (range, y) 26 (16-36) 
Median weight at gestational 
week 36 (kg) (range, kg) 61 (51-71) 
Duration of antenatal ZDV therapy (d) 
14-28 (n) (%) 0 
29-42 (n) (%) 0 
43-56 (n) (%) 0 
> 56 (n) (%) 0 
Labor and delivery 
Median duration of labor (min) 
(range, min) 507 (57-i 247) 
Median time of membrane 
rupture to delivery (min) (range, min) 186 (61835) 
Type of delivery (n) (%) 
Vaginal delivery 48 (I 00) 
Cesarean section 
After membrane rupture 0 (0) 
Before membrane rupture 0 (0) 
Infants 
Median gestational age (wk) 
(range, wk) 39 (34-41) 
Median birth weight (g) 
(range, 9) 2945 (1580-3590) 
25 (2036) 
62 (44-83) 
26 (55) 
17 (36) 
3 (6) 
1 (2) 
712 (O-l 684) 
217 (o-1 564) 
40 (85) 
6 (13) 
1 (2) 
39 (37-42) 
3130 (2390-3750) 
28 (17-37) 
61 (48-93) 
18 (64) 
7 (25) 
2 (7) 
1 (4) 
732 (O-l 466) 
77 (O-l 227) 
22 (79) 
4 (14) 
2 (7) 
38 (37-42) 
3070 (2520-4060) 
26 (19-36) 
63 (47-71) 
5 (38) 
6 (46) 
0 (0) 
2 (15) 
0.837* 
0.787* 
0.314+* 
851 (178-l 324) 
355 (15-994) 
9 (69) 
4 (31) 
0 (0) 
0.209* 
0.117* 
O.OOl~§ 
40 (38-40) 0.276* 
3070 (2540-4410) 0.183* 
ZDV = zidovudine. *Kruskal-Wallis test; ffisher’s exact test; *comparing group 2, 3, and 4; §P = 0.347 when comparing group 2, 3, and 4, 
to late antenatal ZDV (group 3), and 13 received late 
antenatal, intrapartum, and immediate neonatal ZDV 
syrup (group 4). There were no statistically significant 
differences among study groups in the characteristics of 
the mothers. Duration of antenatal ZDV prophylaxis was 
comparable in groups 2,3, and 4 (P = 0.314). There were 
more cases of delivery by cesarean section in group 2, 
3, and 4 than in group 1 (P = O.OOl>, but the proportion 
of cases having cesarean section before amniotic mem- 
brane rupture was similar (P = 0.323) and there was no 
statistically significant difference in types of delivery 
among groups 2,3, and 4 (P = 0.347). Postpartum dura- 
tion when ZDV syrup was initiated in the neonates was 
less than 30 minutes in 56%, less than 1 hour in 70%, less 
than 2 hours in 95%, and less than 18 hours in all cases. 
All infants in groups 3 and 4 received oral neonatal ZDV 
for 4 to 6 weeks, and 90% for 6 weeks. 
Vertical HIV- 1 Transmission 
Human immunodeficiency virus type l-infection status 
of all infants was diagnosed by anti-HIV tests. Of 136 
infants of HIV-infected mothers, 132 were at least 15 
months of age at the time of data analysis, and four infants 
who were 9 to 14 months old had had negative anti-HIV 
tests twice. 
The estimated vertical HIV infection rates of differ- 
ent ZDV prophylaxis regimens are presented in Table 2. 
They were 11 of 48 (22.9%; 95% CI = 12.0-37.3) of the 
children in the non-ZDV group, and 10 of 47 (21.3%; 95% 
CI = 10.7-35.7) in the late antenatal ZDV group, which 
had no statistically significant difference (RR = 0.93; 95% 
CI = 0.43-1.98). Since the rates of vertical transmission 
and characteristics of mothers and infants are similar in 
the two groups, data were combined as an HIV trans- 
mission rate of 21 of 95 (22.1%; 95% CI = 14.2-31.8). 
Addition of neonatal ZDV to the late antenatal ZDV 
regimen decreased the infection rate to 0 of 28 (0%; 95% 
CI = O-12.3). In addition, no HIV transmission occurred 
in 13 infants who received intrapartum intravenous ZDV 
in addition to antenatal and neonatal ZDV An estimated 
0% (95% CI = O-8.6) of the infants who received imme- 
diate neonatal ZDV with or without intrapartum ZDV 
were infected, as compared with 22.1% (95% CI = 
14.2-31.8) of those receiving no ZDV or only late ante- 
natal ZDV (P < 0.001). 
Prophylaxis regimens were alternately practiced 
between late antenatal ZDV regimens without (group 2) 
or with (group 3) neonatal ZDV during April 1995 to 
December 1998. There were consistent findings that the 
two subgroups of group 2 (late antenatal ZDV) had sim- 
ilar transmission rates (5/26 and 5/21), and that none of 
infants in the two subgroups of group 3 (late antenatal 
plus neonatal ZDV) were HIV infected (O/12 and O/16). 
DISCUSSION 
The study showed no protective effect against vertical 
HIV-l transmission in a breastfeeding population of a 
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Table 2. Effects of Different Zidovudine (ZDV) Prophylactic Regimens on Vertical HIV Transmission Rates 
H/V Transmission Rates 
Relative Risk 
Group Study Periods Prophylaxis Regimen Number Percentage (95% CI) (95% cl)* 
1 Nov. ‘St-Mar. ‘96 No ZDV 1 l/48 22.9 (12.0-37.3) 1 .oo 
2 Apr. ‘95-Jan. ‘98 10147 21.3 (10.7-35.7) 0.93 
a. Apr. ‘95-Jan. ‘97 250 mg bid oral ZDV 5126 19.2 (6.6-39.3) (0.43-l .98) 
b. Sep. ‘97-Jan. ‘98 in late pregnancy 5121 23.8 (8.2-47.2) 
3 Jan. ‘97-Dec. ‘98 250 mg bid ZDV O/28 0.0 (0.0 -12.3) 0.00 
a. Jan. ‘97-Aug. ‘97 in late pregnancy, o/12 0.0 (0.0-26.5) (O.OO-0.59)+ 
b. Jan. ‘98-Dec. ‘98 and neonatal ZDV syrup O/16 0.0 (0.0-20.6) 
4 Jan. ‘98-Feb. ‘99 250 mg bid oral ZDV in O/l 3 0.0 (0.0 -24.7) 0.00 
late pregnancy, intravenous (0.00-l .35)+ 
ZDV during labor, and 
neonatal ZDV syrup 
l&2 Nov. ‘91-Jan. ‘98 No ZDV or only 21/95 22.1 (14.2-31.8) 1.00 
antenatal ZDV 
3&4 Jan. ‘97-Feb. ‘99 Any regimen consisting of o/41 0.0 (O.O-8.6)$ 0.00 
immediate neonatal ZDV (O.OO-0.40)+ 
*Group 1 served as the reference group in comparison with group 2, 3, and 4; and group 1 & 2 was the reference group in comparison with group 3 & 4. Cl = 
confidence interval. +Exact confidence intervals of odds ratio; *P < 0.001 for comparison with the reference group 1 or group 1 & 2. 
prophylactic regimen consisting of late antenatal ZDV 
given twice a day for 2 to 6 weeks without an intra- 
pat-turn or neonatal component. There were more cases 
of delivery by cesarean section in the ZDV groups than 
the non-ZDV group, but cesarean section was performed 
after amniotic membrane rupture in almost all cases. 
There was no difference among the four groups in the 
proportion of cases having cesarean section performed 
before membrane rupture, which would affect the trans- 
mission rates.” This study also demonstrated that addition 
of immediate neonatal ZDV given orally within 2 hours 
after birth for 4 to 6 weeks, resulted in a highly protec- 
tive effect against vertical HIV transmission. Two pairs of 
alternate practices between antenatal ZDV regimen and 
a regimen consisting of antenatal ZDV plus immediate 
neonatal ZDV showed consistent findings. 
Several reports have demonstrated that antenatal ZDV 
played a role in prevention of vertical HIV-l infec- 
tion.2-6~‘2-‘4 Most participants received oral ZDV 100 mg, 
five times daily during pregnancy with or without oral 
ZDV during labor, and without neonatal ZDV,5-6~‘2-‘4 or 
received antenatal ZDV; 300 mg, twice daily and every 3 
hours during labor.2-4 None of the previous reports that 
demonstrated protective effects of antenatal regimens 
consisted of twice daily doses of ZDV without the drug 
given during labor and intrapartum, as is being reported 
from this study. Since the interval between doses was 12 
hours, the duration between the last dose of ZDV and 
childbirth could be too long, which resulted in inade- 
quate protective concentration during delivery and after 
birth, when HIV was inoculated and infected. Phaupradit 
and colleagues reported in 30 pregnant women from 
group 2 of this study that the duration between the last 
dose of ZDV and delivery was 16.5 + 6.0 h and that 
umbilical cord serum concentration of ZDV did not 
achieve therapeutic level in all, but there was no infor- 
mation about the effect on viral loads.15 Maternal HIV-l 
viral load was reported as a risk factor for vertical trans- 
mission,‘6-‘9 and antenatal ZDV treatment had an effect 
in lowering maternal viral concentration at delivery, 
which was partly responsible for decreasing risks of ver- 
tical infection.ZJT The antenatal ZDV component in this 
study might have had some effect on decreasing mater- 
nal viral loads that was not enough to affect the risk for 
transmission but might have contributed to protection 
by enhancing the protective effect of the immediate 
neonatal component. Information about viral loads and 
immunologic status of the mothers was not available in 
this study, but none of them was severely ill during preg- 
nancy or delivery. 
This study also demonstrated a high protective 
effect against vertical HIV-l transmission when the inef- 
fective antenatal regimen was accompanied by im- 
mediate neonatal ZDV, which suggested a high impact 
of the neonatal component. Wade and co-workers 
reviewed data from the HIV polymerase chain reaction 
(PCR) testing service of the NewYork State Department 
of Health, and concluded that there were reductions in 
the rates of perinatal transmission of HIV-l even with 
the use of abbreviated regimens that were begun intra- 
partum or in the first 48 hours of life.5 The subcatego- 
rized data suggested that those who received ZDV 
within 12 hours after birth might have had a lower risk 
for HIV infection than those who received the drug at 
12 to 24 hours (l/17 vs. l/4).* Fiscus and colleagues, in 
an observational study, showed that three of seven 
neonates given oral ZDV within 48 hours after birth 
developed HIV-l infection.’ This represents a high trans- 
mission rate, although two of the three infants had in 
utero infection. The theory that antenatal and neonatal 
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regimens should not prevent in utero transmission is 
supported by a study by Shaffer et al.* Two studies in 
Bangkok reported that in utero HIV-1 transmission rates 
were approximately 5.5 and 6.7~h.~)‘~ Failure of pro- 
phylaxis due to in utero transmission did not occur in 
this study, which could be explained by the low inci- 
dence of in utero transmission in the Bangkok popula- 
tion and by the small sample size in the study. 
The factors responsible for the high rate of effec- 
tiveness of this neonatal regimen could be the immedi- 
ate administration of ZDV after birth and the regularity 
and reliability of administration. The immediateness of 
administration of neonatal ZDV may be more important 
in a situation in which the intrapartum component has 
not been administered than in cases in which it has been 
given. The limitation of this report is that information 
was derived from an observational study and the effect 
of the antenatal component, which was not effective by 
itself, could not be confidently excluded. A randomized 
controlled trial would provide stronger evidence. 
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